

on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Benjamin W. McDonough, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington DC 20551-0001, not later than April 7, 2026.

A. Federal Reserve Bank of Kansas City (Jeffrey Imgarten, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001. Comments can also be sent electronically to KCApplicationComments@kc.frb.org:

1. *R.K. Buerge Family, L.P., Robin K. Buerge Revocable Trust, Robin Buerge, as trustee, Robin K. Buerge Spouse's Trust, Austin Buerge, as trustee, and both trusts as general partners of R.K. Buerge Family, L.P., all of Tulsa, Oklahoma*; to join the Buerge Family Control Group, a group acting in concert, to acquire voting shares of Grand Capital Corporation, and thereby indirectly acquire voting shares of Grand Bank, both of Tulsa, Oklahoma. Robin Buerge and Austin Buerge are members of the Buerge Family Control Group and were each previously permitted by the Federal Reserve System to acquire control of voting shares of Grand Capital Corporation.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Associate Secretary of the Board.

[FR Doc. 2026-05629 Filed 3-20-26; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Committee on Vital Health and Statistics (NCVHS); Notice of Charter Renewal

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of charter renewal.

SUMMARY: The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), announces the renewal of the charter of the National Committee on Vital Health and Statistics (NCVHS).

FOR FURTHER INFORMATION CONTACT:

Naomi Michaelis, MPA, Acting Designated Federal Officer, National Committee on Vital Health and Statistics (NCVHS), Centers for Disease Control and Prevention, Department of Health and Human Services, 3311 Toledo Road, Hyattsville, Maryland 20782. Telephone: (301) 458-4202; Email: nmichaelis@cdc.gov.

SUPPLEMENTARY INFORMATION: CDC is providing notice under 5 U.S.C. 1001-1014 of the renewal of the charter of the National Committee on Vital Health and Statistics (NCVHS), Centers for Disease Control and Prevention, Department of Health and Human Services. This charter has been renewed for a two-year period through January 22, 2028.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2026-05570 Filed 3-20-26; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2026-N-2366]

Commissioner's National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Public hearing; request for comments.

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is announcing a public hearing related to the Commissioner's National Priority Voucher (CNPV) Pilot Program, which is designed to significantly reduce review times for qualifying new drug applications (NDAs), biologics license applications (BLAs), and manufacturing or efficacy supplements through enhanced regulatory engagement and streamlined review procedures. The CNPV Pilot Program is intended to expedite approvals for products that align with critical U.S. national health priorities while maintaining FDA's rigorous scientific and regulatory standards. We are holding this public hearing to obtain feedback and perspectives regarding the CNPV Pilot Program, including feedback on the eligibility criteria, voucher selection processes, sponsor responsibilities, FDA review procedures, and program implementation.

DATES: The public hearing will be held with an in-person and virtual option (*i.e.*, hybrid) on June 12, 2026, from 1:00 p.m. to 4:00 p.m. Eastern Time. Meeting registration, including requests for participation in the public hearing, can be found at the following website: <https://www.fda.gov/news-events/commissioners-national-priority-voucher-cnpv-pilot-program-public-hearing-06122026>. All requests for participation, including for those who wish to present during the public hearing, must be received by 11:59 p.m., May 1, 2026, through the meeting registration page. Questions about meeting registration and participation should be sent to CommissionerVoucher@fda.hhs.gov, and include the title of this notice: "Commissioner's National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments"). See the **SUPPLEMENTARY INFORMATION** section for attendance and registration information.

Either electronic or written comments on this public hearing will be accepted